How many insider trades does FilingIQ track for SLGL?

FilingIQ tracks 27 Form 4 insider transactions for SLGL (Sol-Gel Technologies Ltd.), covering filings from Nov 20, 2025 onwards. 4 of those were filed in the last 90 days.

Are SLGL insiders net buyers or net sellers?

Across the full Form 4 history for SLGL, 27 transactions (100%) were open-market purchases and 0 (0%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.

Where does SLGL insider data come from?

Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ parses the raw XML, normalises insider identity across reporting variations, and scores each trade on its multi-factor composite model.

What sector is SLGL in?

Sol-Gel Technologies Ltd. (SLGL) is classified in the Healthcare sector, specifically Biotechnology, with a current market capitalisation of $222.89M.

SLGL insider trading

NasdaqCM Healthcare

Sol-Gel Technologies Ltd. — scored insider trade history from SEC Form 4 filings, parsed and contextualised by FilingIQ.

Total Form 4 trades

Last 90 days

Buys / sells

100% / 0%

Market cap

$222.89M

About Sol-Gel Technologies Ltd.

Sol-Gel Technologies Ltd., together with its subsidiary Sol-Gel Technologies Inc., develops topical dermatological drugs for patients with severe skin conditions in Israel, China, Switzerland, Canada, the United States and internationally. The company offers Twyneo, a once-daily, non-antibiotic topical cream for the treatment of acne vulgaris; and Epsolay, a once-daily topical cream for the treatment of papulopustular (subtype II) rosacea. It also develops SGT-610 that is in Phase 3 clinical trials for the treatment of Gorlin Syndrome; and SGT-210, which has completed Phase I clinical trial, to treat olmsted syndrome. It has collaboration with Padagis Israel Pharmaceuticals Ltd; and license agreements with Galderma Holding SA and Searchlight Pharma Inc. Sol-Gel Technologies Ltd. was incorporated in 1997 and is headquartered in Ness Ziona, Israel.

Company website: www.sol-gel.com

SLGL insider activity at a glance

FilingIQ has scored 27 insider transactions for SLGL since Nov 20, 2025. The most recent filing in our index is dated May 13, 2026.

Across the full history, 27 open-market purchases and 0 open-market sales were filed under transaction codes P and S respectively. Compensatory share awards (code A) and option exercises (code M) are tracked separately and not counted here.

The average FilingIQ composite score on SLGL insider trades is 46.5/100, produced by FilingIQ's multi-factor Form 4 model. Model framework documented at methodology.

View live SLGL trades on FilingIQ Raw filings on SEC EDGAR

Other Healthcare tickers with recent insider activity

UTHR 1,098

UNITED THERAPEUTICS Corp

APLS 279

Apellis Pharmaceuticals, Inc.

KMDA 218

KAMADA LTD

BMY 185

BRISTOL MYERS SQUIBB CO

ADPT 184

Adaptive Biotechnologies Corp

GH 169

Guardant Health, Inc.

ISRG 166

INTUITIVE SURGICAL INC

VTRS 165

Viatris Inc

Frequently asked

How many insider trades does FilingIQ track for SLGL?: FilingIQ tracks 27 Form 4 insider transactions for SLGL (Sol-Gel Technologies Ltd.), covering filings from Nov 20, 2025 onwards. 4 of those were filed in the last 90 days.
Are SLGL insiders net buyers or net sellers?: Across the full Form 4 history for SLGL, 27 transactions (100%) were open-market purchases and 0 (0%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.
Where does SLGL insider data come from?: Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ parses the raw XML, normalises insider identity across reporting variations, and scores each trade on its multi-factor composite model.
What sector is SLGL in?: Sol-Gel Technologies Ltd. (SLGL) is classified in the Healthcare sector, specifically Biotechnology, with a current market capitalisation of $222.89M.

Methodology & sources

Every SLGL insider transaction shown on FilingIQ is parsed directly from a public SEC Form 4 XML filing. Insider identity is normalised across reporting variants (CIK changes, name spellings, related-party indirect holdings). The FilingIQ composite score is documented in full on the team page and algo disclosure. Not investment advice; see disclaimer.